Fasting Insulin vs HOMA-IR
Fasting insulin is a direct measure. HOMA-IR combines fasting insulin and fasting glucose into a single insulin-resistance index. HOMA-IR is more sensitive for early insulin resistance than either marker alone.
Fasting insulin is the anchor marker on the metabolic panel and is tracked across recalibration cadence.
HOMA-IR is decisive when fasting insulin and glucose are borderline or when early insulin resistance is suspected.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Do I need both?
HOMA-IR requires fasting insulin and fasting glucose — both are drawn together.
Which is the modern standard?
HOMA-IR is the preferred decisional index; fasting insulin remains the underlying anchor.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment